OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

Morningstar brands and products Company Portfolio ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly (NYSE:LLY) just sent a Cease-and-Desist to OrderlyMeds over its compounded version of tirzepatidea move that's ruffled more than feathers. But instead of retreating, the healthtech upstart ...